Mexico Hepatitis A Therapeutics Market Analysis

Mexico Hepatitis A Therapeutics Market Executive Summary

The Mexico Hepatitis A Therapeutics Market was valued at $11.06 Mn in 2023 and is predicted to grow at a CAGR of 2.45% from 2023 to 2030 to $13.10 Mn by 2030.

Hepatitis A is a contagious liver disease typically transmitted through contaminated food or water or close personal contact with an infected individual, presenting with varying severity from mild illness lasting weeks to more severe complications lasting months. It is notably prevalent in Mexico, with significant seroprevalence rates across various age groups. The increasing incidence, particularly in regions with inadequate sanitation and limited access to clean water, stimulates demand for treatments and preventive measures like vaccination programs. Mexico's aging population heightens susceptibility to Hepatitis A infections, posing considerable health risks. Addressing personal hygiene and sanitation challenges is pivotal in mitigating the spread of Hepatitis A and lessening its public health impact in Mexico.

Mexico has a high prevalence of Hepatitis A, with an average seroprevalence of 69.3%, ranging from 58.8% in adolescents to 83% in young adults, making Hepatitis A the primary cause of viral hepatitis in the general population and the most common viral infection among children. Factors including growing prevalence, an aging population, and personal hygiene and sanitation challenges propel the market, while factors like lack of healthcare infrastructure, high cost, and limited inclusion in national immunization programs restrain the market.

Market Dynamics

Market Growth Drivers

Rising Prevalence: Hepatitis A is increasingly common in Mexico, emerging as the primary cause of viral hepatitis in the general population (79%) and the most prevalent viral infection among children. The seroprevalence of Hepatitis A in Mexico is significant, with an average weighted HAV (Hepatitis A Virus) seroprevalence of 69.3%, varying from 58.8% in adolescents to 83.0% in young adults. This widespread prevalence highlights the significant impact of Hepatitis A across the country. The growing incidence of Hepatitis A infections in Mexico, particularly in regions with inadequate sanitation and limited access to clean water, is spurring demand for effective treatments and preventive measures such as vaccination programs and enhanced healthcare strategies.

Aging Population: Mexico's aging population is increasingly susceptible to Hepatitis A infections, with anti-HAV seropositivity reaching 96.9% in adults aged ≥ 20 years. As the population ages, the number of vulnerable individuals is rising, posing substantial health risks, including liver failure and mortality. Recent data suggests a shift in the age groups affected by Hepatitis A, with a declining incidence trend and a notable increase observed during 2017-2019. This indicates that as Mexico's population continues to age, the burden of Hepatitis A is likely to escalate among older adults, emphasizing the need for targeted therapeutics and preventive measures, thus driving the market.

Poor Hygiene and Sanitation Practices: Inadequate personal hygiene and sanitation practices significantly contribute to the demand for Hepatitis A therapeutics in Mexico. Issues related to water disinfection, lack of proper handwashing facilities, and inadequate wastewater disposal impact hygiene practices, with many households failing to disinfect drinking water and lacking appropriate handwashing facilities. This creates opportunities for pharmaceutical companies and healthcare providers to cater to the needs of affected populations with effective treatments and preventative measures.

Market Restraints

Lack of healthcare infrastructure: The limited availability of healthcare facilities equipped to handle liver diseases, such as liver transplants, in Mexico hinders the growth of the Hepatitis A therapeutics market. Investments in healthcare infrastructure are necessary to support the effective management of Hepatitis A and other liver diseases.

High Cost: Hepatitis A vaccines, ranging from $26 to $66 per dose for uninsured adults and $40 to $58 per dose at private healthcare facilities in Mexico, are a significant barrier to their widespread adoption. Compared to other childhood immunizations, this high cost hinders the inclusion of Hepatitis A vaccines in Mexico's National Immunization Program. The relatively high price of Hepatitis A vaccines limits access to the vaccines and restrains the market growth for Hepatitis A therapeutics in Mexico.

Limited Inclusion in National Immunization Programs: The lack of inclusion of Hepatitis A vaccines in Mexico's National Immunization Program limits access and uptake of the vaccine, impacting the market for Hepatitis A therapeutics.

Regulatory Landscape and Reimbursement Scenario

The reimbursement scenario for Hepatitis A therapeutics in Mexico is influenced by various factors, including patient situation, payer type, specific medications used, and cost-effectiveness considerations. Regulatory bodies like COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios) and the Secretaría de Salud (Mexican Secretariat of Health) oversee drug approvals, registration, and compliance with health regulations, ensuring compliance with regulatory standards and safeguarding public health.

Public payers like Instituto Mexicano del Seguro Social (IMSS) and Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) may cover Hepatitis A treatments for high-risk individuals, such as unvaccinated or incompletely vaccinated patients with clinically significant infections, immunocompromised individuals, and those needing post-exposure prophylaxis, subject to prior authorization. Private health insurance coverage varies based on plan details and formularies, with some offering broader coverage and others having stricter criteria. The limited number of approved Hepatitis A medications and Mexico's focus on vaccination may impact reimbursement decisions.

Competitive Landscape

Key players

Here are some of the major key players in the Hepatitis A Therapeutics Market:

• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Zydus Cadilla
• Sanofi
• GlaxoSmithKline (GSK)
• Takeda
• CVS Health Corporation